Scalp and Cranium Neurobrucellosis



Fig. 3.1
Plain radiograph demonstrating a radiolucent osteolytic lesion in the left supraorbital region in the same patient (white arrow) (From Sohn et al. [47], with permission)



Magnetic resonance imaging (MRI) has a high sensitivity, specificity, and accurate rates for identification of bone, periosteal, and soft tissue involvements [11]. MRI is useful for identifying early bone marrow changes, osteomyelitis, and subperiosteal or soft tissue collections such as abscesses. On MRI, active inflammation shows decreased signal on T1-weighted images and increased signal in T2-weighted images and fat-suppression sequences (Fig. 3.2), [47]. In T1-weighted images, high signal intensity between the abscess and sclerotic bone marrow, called “penumbra sign,” is characteristic of osteomyelitis. The use of contrast agents is generally not necessary for MRI [11].

A334675_1_En_3_Fig2_HTML.jpg


Fig. 3.2
Magnetic resonance imaging of the brain revealing a hypointense area on T1-weighted image (a) and hyperintense area on T2-weighted image (b) in the frontal bone, with a pathological diagnosis of brucellar granulomatous lesion (white arrows) (From Sohn et al. [47], with permission)

Scintigraphy is useful when the infection cannot be localized or multifocality is suspected [13]. The three-phase bone scan is usually performed; it consists of a nuclear angiogram (2–5 s after injection), a blood pool phase (5–10 min after injection), and a delayed phase (2–4 h after injection). In the first two phases, increased uptake can be caused by any inflammation that increased the blood flow. However, the increased uptake in the third (delayed) phase reflects the osteoblastic activity. Tc-99 m methylene diphosphonate and Ga 67 citrate are sensitive agents for detecting bone involvement, but they have a low specificity (Fig. 3.3) [47]. A higher specificity has been shown with Tc-99 m polyclonal human immunoglobulin, Tc-99 interleukin-8, In-111 granulocytes, radiolabeling leukocytes, and monoclonal Fab fragments [21, 25, 44].

A334675_1_En_3_Fig3_HTML.jpg


Fig. 3.3
Tc-99 m MDP bone scintigraphy showing a focal increased tracer uptake in the left supraorbital region in a patient with symptoms of fever and myalgia for 2 weeks (black arrows) (From Sohn et al. [47], with permission)

Computed tomography (CT) indications for osteomyelitis are lack of availability of MRI or contraindications to MRI, the arrangement of the surgical intervention to debridement of sequestra, and identification of bone damage in chronic osteomyelitis. CT findings of osteomyelitis are increased bone marrow density, periosteal new bone formation, and periosteal purulence.

Ultrasonography usually does not help for the diagnosis of osteomyelitis. It can be used for detection of fluid collections and improve the percutaneous drainage procedures.

Ioannou et al. [24] demonstrated that positron emission tomography-computed tomography (PET-CT) scan may provide useful information in osteoarticular brucellosis. Fluorodeoxyglucose uptakes of infected tissues increased as standard uptake value max values. Sensitivity and specificity of the PET-CT is ranging 94–100 % and 87–100 %, respectively. However, this study has been limited to a small number of patient, and therefore, further studies are necessary to clarify these results. PET-CT is better than the other modalities to show the spread of infection and multifocal lesions in a multisystemic brucellosis disease.



3.3.2.6 Treatment


Treatment is used to shorten the duration of symptoms and to prevent complications and recurrence of the disease. Doxycycline, rifampin, trimethoprim-sulfamethoxazole, ceftriaxone, streptomycin, and ciprofloxacin have been proved very effective in many studies [6, 7, 18, 51]. Monotherapies or a combination of two or three drugs is currently used. Therapeutic failure was more common when monotherapy is used. Duration of the therapy depends on the condition of the patient, presence of complications, and time from onset of symptoms to beginning of the treatment. A minimum of 6 weeks of combined antibiotic treatment has a lower frequency of relapse.




3.4 Prevention and Prognosis


Brucellosis is not usually transmitted from human to human. Nevertheless, rarely, transmission of the Brucella by bone marrow transplantation, blood transfusion, sexual intercourse, ingestion of breast milk, and through the placenta has been reported [1, 19, 34, 37, 42].

Humans can be prevented from brucellosis by eradication of infection in animals by vaccination and other veterinary control methods. There is no brucellosis vaccine for humans yet [14, 33, 35]. In endemic regions, pasteurization of products such as milk, butter, cheese, etc., is an effective security precaution for the prevention of the diseases. Unpasteurized products at the dairy and undercooked meat or other animal products should not be ingested. Precautions should be taken for occupational disease such as hygiene and protective clothing or equipment [4, 10, 22, 40, 54].

Reappearance of the symptoms and clinical findings with or without positive culture is defined as recurrence of brucellosis [52]. The relapse rate varies from about 5 to 45 % depending on the treatment protocol used [8, 46, 52]. It often occurs 6 months after termination of the treatment and is often associated with poor compliance to therapy. Relapse tends to be milder than the primary disease [27, 46, 48].


Conclusion






  • Scalp and cranial bone involvement is considered to be extremely rare.


  • The most frequent findings are immobile, non-fluctuating lump for cranial osteomyelitis and erythema brucellum, maculopapular eruptions, erythema nodosum-like lesions for scalp involvement.


  • Due to the lack of specific skin and osseous lesions, a thorough history, clinical evaluation, serological tests, and culture are needed for diagnosis


  • Plain radiography, MRI, and bone scintigraphy are the most frequently used imaging methods for cranial brucellosis


  • Combined antibiotic therapy protocols for at least 6 weeks have therapeutic success. Surgery may be needed when abscesses are present.


References



1.

Akçakuş M, Esel D, Cetin N, Kisaarslan AP, Kurtoglu S (2005) Brucella melitensis in blood cultures of two newborns due to exchange transfusion. Turk J Pediatr 47:272–274PubMed


2.

Akcali C, Savas L, Baba M, Turunc T, Seckin D (2007) Cutaneous manifestations in brucellosis: a prospective study. Adv Ther 24:706–711PubMedCrossRef


3.

Ali-Eldin FA, Abdelhakam SM, Ali-Eldin ZA (2011) Clinical spectrum of fever of unknown origin among adult Egyptian patients admitted to Ain Shams University Hospitals: a hospital based study. J Egypt Soc Parasitol 41:379–386PubMed


4.

Al-Shaar L, Chaaya M, Ghosn N, Mahfoud Z (2014) Brucellosis outbreak in Chouf district of Lebanon in 2009: a case control study. East Mediterr Health J 20:250–256PubMed


5.

Andriopoulos P, Tsironi M, Deftereos S, Aessopos A, Assimakopoulos G (2007) Acute brucellosis: presentation, diagnosis, and treatment of 144 cases. Int J Infect Dis 11:52–57PubMedCrossRef


6.

Ariza J, Servitje O, Pallares R, Fernandez VP, Rufi G, Peyri J, Gudiol F (1989) Characteristic cutaneous lesions in patients with brucellosis. Arch Dermatol 125:380–383PubMedCrossRef


7.

Asadipoova K, Dehghanian A, Omrani GH, Abbasi F (2011) Short-course treatment in neurobrucellosis: a study in Iran. Neurol India 59:101–103CrossRef


8.

Aygen B, Doganay M, Sumerkan B, Yildiz O, Kayabas U (2002) Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med Mal Infect 32:485–493CrossRef

Dec 11, 2016 | Posted by in NEUROLOGY | Comments Off on Scalp and Cranium Neurobrucellosis

Full access? Get Clinical Tree

Get Clinical Tree app for offline access